WO2004045526A3 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms - Google Patents
Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms Download PDFInfo
- Publication number
- WO2004045526A3 WO2004045526A3 PCT/US2003/036557 US0336557W WO2004045526A3 WO 2004045526 A3 WO2004045526 A3 WO 2004045526A3 US 0336557 W US0336557 W US 0336557W WO 2004045526 A3 WO2004045526 A3 WO 2004045526A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chemokine
- growth
- neoplasms
- inhibition
- associated receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering antichemokine antibodies. It is possible to identify the particular chemokines, that are over-expressed in the tumor using methods of the invention, and administer antibodies against that over-expressed chemokine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003291549A AU2003291549A1 (en) | 2002-11-15 | 2003-11-14 | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42634702P | 2002-11-15 | 2002-11-15 | |
US60/426,347 | 2002-11-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004045526A2 WO2004045526A2 (en) | 2004-06-03 |
WO2004045526A3 true WO2004045526A3 (en) | 2005-03-31 |
Family
ID=32326333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/036557 WO2004045526A2 (en) | 2002-11-15 | 2003-11-14 | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
Country Status (3)
Country | Link |
---|---|
US (9) | US7919083B2 (en) |
AU (1) | AU2003291549A1 (en) |
WO (1) | WO2004045526A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027078A1 (en) * | 1997-11-21 | 1999-06-03 | Human Genome Sciences, Inc. | Chemokine alpha-5 |
US20120135415A1 (en) * | 2002-11-15 | 2012-05-31 | Morehouse School Of Medicine | Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
US20120064089A1 (en) * | 2002-11-15 | 2012-03-15 | Morehouse School Of Medicine | Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration |
US8512701B2 (en) * | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
US20100143899A1 (en) * | 2005-05-17 | 2010-06-10 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
KR101484025B1 (en) * | 2006-04-21 | 2015-01-19 | 얀센 바이오테크 인코포레이티드 | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
US8445442B2 (en) * | 2007-04-26 | 2013-05-21 | University Of Vermont And State Agricultural College | CCL18 and CCL3 methods and compositions for detecting and treating cancer |
US20090028866A1 (en) * | 2007-07-27 | 2009-01-29 | John Wayne Cancer Institute | USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
KR101051435B1 (en) * | 2008-10-22 | 2011-07-22 | 한국생명공학연구원 | Colorectal cancer diagnostic kit using colorectal cancer-related markers and colorectal cancer diagnostic method using the same |
KR101682257B1 (en) * | 2008-10-31 | 2016-12-05 | 도레이 카부시키가이샤 | Immunoassay method for human cxcl1 protein |
PT2356462T (en) * | 2008-11-11 | 2017-04-07 | Univ Michigan Regents | Anti-cxcr1 compositions and methods |
WO2011040428A1 (en) * | 2009-09-29 | 2011-04-07 | 学校法人慶應義塾 | Anti-tumor agent and method for screening for same |
WO2012031099A2 (en) | 2010-09-02 | 2012-03-08 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
CN106177930A (en) * | 2010-12-14 | 2016-12-07 | 吉安特科技股份有限公司 | Anti-cxcl 13 antibodies and anti-CXCR5 antibody purposes in the treatment or detection of malignant tumor |
US20130338033A1 (en) * | 2011-01-27 | 2013-12-19 | Virginia Commonwealth University | Diagnostic and Prognostic Markers for Metastasis |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
DK2717941T3 (en) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Treatment of cancer |
WO2013131010A2 (en) * | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
JP6193275B2 (en) | 2012-03-02 | 2017-09-06 | ヴァクシネックス, インコーポレイテッド | Methods for treating B cell mediated inflammatory diseases |
TWI467172B (en) * | 2012-10-24 | 2015-01-01 | Po Lin Kuo | Method for selecting candidate for treating breast cancer metastasis |
US9790271B2 (en) | 2013-01-31 | 2017-10-17 | Vaccinex, Inc. | Methods for increasing immunoglobulin A levels |
WO2017140793A1 (en) | 2016-02-16 | 2017-08-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of ccr9 for treating tumor resistance to immune responses |
WO2017140803A1 (en) | 2016-02-16 | 2017-08-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Modulators of tumor immune resistance for the treatment of cancer |
BR112018076281A2 (en) | 2016-06-20 | 2019-03-26 | Kymab Limited | immunocytocin, use of an immunocytocin, method, pharmaceutical composition, method for treating a proliferative disease in an animal, nucleic acid, vector, host and antibody or fragment thereof |
EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
US10980739B2 (en) | 2016-12-14 | 2021-04-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
CN107964045B (en) * | 2017-12-18 | 2021-04-23 | 南京医科大学 | Human-mouse chimeric anti-CXCR 2 full-molecular IgG and application thereof |
US11028164B2 (en) * | 2018-09-18 | 2021-06-08 | I-Mab Biopharma Us Limited | Anti-CXCL13 antibodies |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050461A1 (en) * | 1998-03-30 | 1999-10-07 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6723520B2 (en) * | 1996-07-05 | 2004-04-20 | Schering Corporation | Antibodies that bind chemokine teck |
US6110695A (en) * | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
US6863887B1 (en) * | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
US6962980B2 (en) * | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6329159B1 (en) * | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
JP2004500412A (en) * | 2000-03-31 | 2004-01-08 | アイデック ファーマスーティカルズ コーポレイション | Combination of anti-cytokine antibody or antagonist and anti-CD20 for treatment of B-cell lymphoma |
EP1339872A2 (en) * | 2000-09-19 | 2003-09-03 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
US20040029114A1 (en) * | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
AU2002303194A1 (en) * | 2001-03-30 | 2002-10-15 | Origene Technologies, Inc | Differentially-expressed and up-regulated polynucleotides and polypeptides in breast cancer |
CA2445532A1 (en) * | 2001-04-27 | 2002-11-07 | Sunnybrook & Women's College Health Sciences Centre | Breast cancer-associated genes and uses thereof |
US7282338B2 (en) * | 2001-06-07 | 2007-10-16 | Chemocentryx, Inc. | Cell migration assay |
US7189507B2 (en) * | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US20110281814A1 (en) * | 2009-01-30 | 2011-11-17 | Genzyme Corporation | Methods and compositions for treating breast cancer |
-
2003
- 2003-11-14 AU AU2003291549A patent/AU2003291549A1/en not_active Abandoned
- 2003-11-14 WO PCT/US2003/036557 patent/WO2004045526A2/en not_active Application Discontinuation
- 2003-11-14 US US10/712,398 patent/US7919083B2/en not_active Expired - Fee Related
-
2010
- 2010-12-14 US US12/967,795 patent/US20110091528A1/en not_active Abandoned
- 2010-12-14 US US12/967,273 patent/US8097250B2/en not_active Expired - Fee Related
- 2010-12-14 US US12/967,816 patent/US20110081407A1/en not_active Abandoned
- 2010-12-15 US US12/968,698 patent/US20110091529A1/en not_active Abandoned
- 2010-12-15 US US12/968,659 patent/US20110081408A1/en not_active Abandoned
-
2011
- 2011-01-26 US US13/014,310 patent/US20110150982A1/en not_active Abandoned
- 2011-01-26 US US13/014,240 patent/US20110123603A1/en not_active Abandoned
-
2013
- 2013-05-03 US US13/886,559 patent/US20130243761A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050461A1 (en) * | 1998-03-30 | 1999-10-07 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
Non-Patent Citations (1)
Title |
---|
ZAMBELLO, R. ET AL.: "Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 120, March 2003 (2003-03-01), pages 765 - 773, XP002984890 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003291549A8 (en) | 2004-06-15 |
US20110150982A1 (en) | 2011-06-23 |
US8097250B2 (en) | 2012-01-17 |
US20110081408A1 (en) | 2011-04-07 |
US20110091529A1 (en) | 2011-04-21 |
US20110081406A1 (en) | 2011-04-07 |
US7919083B2 (en) | 2011-04-05 |
US20040170628A1 (en) | 2004-09-02 |
US20110081407A1 (en) | 2011-04-07 |
AU2003291549A1 (en) | 2004-06-15 |
WO2004045526A2 (en) | 2004-06-03 |
US20110091528A1 (en) | 2011-04-21 |
US20130243761A1 (en) | 2013-09-19 |
US20110123603A1 (en) | 2011-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004045526A3 (en) | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms | |
IL245462A0 (en) | Humanized anti-cmet antagonists | |
WO2005044307A3 (en) | Methods of therapy for b cell-related cancers | |
WO2008070042A3 (en) | High potency recombinant antibodies, methods for producing them and use in cancer therapy | |
MY145073A (en) | Anti-glypican 3 antibody | |
MY151032A (en) | Treatment of tnf? related disorders | |
WO2005081854A3 (en) | Egf receptor epitope peptides and uses thereof | |
IL181473A0 (en) | Humanized anti-beta 7 antagonists and uses therefor | |
AU2003294290A8 (en) | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. | |
WO2004080418A3 (en) | Nucleic acid compounds for inhibiting angiogenesis and tumor growth | |
WO2005070043A3 (en) | Methods for treating non-melanoma cancers with paba | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
TW200612988A (en) | Adjuvant therapy with the use of anti-glypican 3 antibody | |
HK1160776A1 (en) | Methods of treating cancer using il-21 and monoclonal antibody therapy | |
WO2004058191A3 (en) | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof | |
WO2006012616A3 (en) | Therapeutic use of anti-tf-antigen antibody | |
WO2006009765A3 (en) | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells | |
MXPA05008794A (en) | Glycorpotein antigen sima135 expressed in metastatic human tumor cells. | |
EP1773883A4 (en) | Antibodies against cancer produced using masked cancer cells as immunogen | |
WO2004074437A3 (en) | Compositions and methods for cancer immunotherapy | |
AU2003215381A1 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
SI1758610T1 (en) | Methods of treating cancer using il-21 and monoclonal antibody therapy | |
MXPA05004126A (en) | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis. | |
AU2002326318A1 (en) | Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer | |
WO2003051312A3 (en) | E2f and cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |